初诊时即有远处转移的头颈癌患者的治疗结局
这项多机构回顾性研究分析了2007至2021年间98例初诊即有远处转移(M1)的头颈鳞状细胞癌(HNSCC)患者,比较接受全身化疗的非姑息组(n=60)与未接受化疗的姑息组(n=38)的总生存(OS)。非姑息组中位OS为15个月(95%CI 10-20),显著长于姑息组的3个月(95%CI 2-5)(p<0.001)。多因素分析显示,局部区域放疗(HR 0.407)、免疫检查点抑制剂(ICI)治疗(HR 0.216)及远处转移灶放疗/手术(HR 0.373)是OS的独立预后因素。
要点
- 非姑息组中位OS为15个月(95%CI 10-20),显著长于姑息组的3个月(95%CI 2-5)(p<0.001)。
- 局部区域放疗(HR 0.407,95%CI 0.197-0.844;p=0.016)与OS改善独立相关。
- ICI治疗(HR 0.216,95%CI 0.088-0.532;p<0.001)及远处转移灶放疗/手术(HR 0.373,95%CI 0.150-0.932;p=0.034)为独立预后因素。
核心结论
- 采用ICI全身治疗联合局部区域或远处转移灶放疗/手术的强化治疗策略,可能为M1期HNSCC患者带来生存获益。
研究设计与样本
- 多机构回顾性研究,纳入2007至2021年间初诊即为M1期的HNSCC患者98例,分为非姑息组(接受全身化疗,n=60)与姑息组(未接受全身化疗,n=38)。
主要发现
- 非姑息组中位OS为15个月(95%CI 10-20),姑息组为3个月(95%CI 2-5),非姑息组显著长于姑息组(p<0.001)。
- 多因素分析显示,局部区域放疗(HR 0.407,95%CI 0.197-0.844;p=0.016)与OS改善独立相关。
- ICI治疗(HR 0.216,95%CI 0.088-0.532;p<0.001)与OS改善独立相关。
- 远处转移灶放疗/手术(HR 0.373,95%CI 0.150-0.932;p=0.034)与OS改善独立相关。
临床怎么用
- 作者认为,采用ICI全身治疗联合局部区域或远处转移灶放疗/手术的强化治疗策略,可能为M1期HNSCC患者带来生存获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) treatment has changed dramatically with the introduction of immune checkpoint inhibitors (ICIs). However, there are few reports of treatment outcomes on HNSCC with distant metastasis (M1) at initial diagnosis, and its treatment strategy has not been standardized. We aimed to analyze the treatment outcome and prognostic factors of patients with HNSCC with initial M1 disease. METHODS: In this multi-institutional retrospective study, 98 patients with HNSCC were initially diagnosed with M1 disease between 2007 and 2021. The patients were divided into the non-palliative (received any systemic chemotherapy, n = 60) and palliative (did not receive systemic chemotherapy, n = 38) groups. Overall survival (OS) was compared between the groups. In the non-palliative group, predictors of OS were explored based on patient characteristics and treatment details. RESULTS: The median OS in the non-palliative group was 15 months (95% confidence interval [CI], 10-20), which was significantly longer than that in the palliative group (3 months, 95% CI, 2-5) (p < 0.001). Multivariate analysis revealed that administration of locoregional radiation therapy (RT) (hazard ratio [HR] 0.407 [95% CI 0.197-0.844]; p = 0.016), ICIs (HR 0.216 [95% CI 0.088-0.532]; p < 0.001) and RT/surgery for distant metastasis (HR 0.373 [95% CI 0.150-0.932]; p = 0.034) were the independent prognostic factors of OS. CONCLUSION: An intensive treatment strategy combining systemic therapy using ICIs with RT/surgery for locoregional or distant metastasis may yield a survival benefit for patients with HNSCC with M1 disease. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:1679-1686, 2024.
引用
- Omata J, Ueki Y, Takahashi Y, et al. Treatment Outcome in Head and Neck Cancer With Distant Metastasis at Initial Diagnosis. Laryngoscope. 2023. PMID: 37698411. doi:10.1002/lary.31047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。